BREAKING NEWS: Japan drugmaker Chugai's Hattori, 3 others awarded over hemophilia medicine
5 Articles
5 Articles
– Recognized for the invention of a bispecific antibody that changed the treatment paradigm through an unconventional approach – Recognized for realizing an innovative drug discovery concept, in which a bispecific antibody assumes the function of coagulation factor VIII, which is deficient in hemophilia A. Offered greater ease of use thanks to a long-lasting effect and […]
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World's Most Respected Scientific Honors
Business Wire India Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs […]
Three Japanese researchers who were selected for the Lasker Award, America's most prestigious medical award, spoke of their joy at a press conference on the 10th. The Lasker Award for Clinical Medicine, announced on the 9th, was awarded to three individuals, including former Senior Fellow at Chugai Pharmaceutical, for their development of Hemlibra, a treatment for hemophilia A. Former Senior Fellow at Chugai Pharmaceutical, Yukihiro Hattori: "I …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
